Inovio submits EMA conditional marketing authorization for VOCERYQ, its DNA immunotherapy for RRP

Inovio Pharmaceuticals filed a Conditional Marketing Authorization (CMA) application with the European Medicines Agency for VOCERYQ, its plasmid DNA‑based therapy for recurrent respiratory papillomatosis (RRP). The product received accelerated approval from the U.S. FDA on 30 Oct 2026 and the company expects to begin U.S. shipments about 60 days after that approval, with a full commercial launch in Q1 2027. European approval would give the company its first market outside the United States for the therapy.

If the EMA grants the CMA, Inovio could add a European market to VOCERYQ’s sales pipeline, potentially increasing revenue and diversifying geographic exposure. The U.S. launch timeline and the orphan‑drug status also support a longer‑term growth outlook for the company.

  • 1Inovio submitted a Conditional Marketing Authorization application to the EMA for VOCERYQ as a treatment for adults with RRP.
  • 2The FDA granted accelerated approval for VOCERYQ on 30 Oct 2026.
  • 3Inovio expects VOCERYQ to be available for order and shipment in the U.S. about 60 days after FDA approval, with a full commercial launch in the first quarter of 2027.
  • 4The European Commission granted orphan‑drug designation to VOCERYQ in 2023.
  • 5The CELLECTRA delivery device used for VOCERYQ carries a CE‑mark in the EU.
  • 6Inovio estimates at least 25,000 people in the United States have active RRP.

Sources